Publish date:

UBS Upgrades Amgen

Shares rise.

Amgen (AMGN) - Get Report rose 2% early Wednesday after a Food and Drug Administration advisory panel rejected a rule that would have reduced top dosages of the company's anemia drugs.

Amgen rose 90 cents to $54.78 after UBS upgraded the stock to neutral from sell, saying the FDA panel's move lifts a cloud over the company's lucrative Epogen and Aranesp franchises. The decision also offers a lift to

Johnson & Johnson

(JNJ) - Get Report

TST Recommends

, which sells the anemia drug Procrit.

Sales of the drugs have fallen since concerns about cardiovascular health issues surfaced in March. Both companies have recently set broad restructuring plans in a bid to bring costs down.